z p ] } v o } v } z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru...
TRANSCRIPT
![Page 1: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/1.jpg)
Regional response to the Global action plan on dementia (Europe)
ADI Conference, Chicago – 27 July 2018
Jean Georges, Executive Director
@JeanGeorgesAE
![Page 2: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/2.jpg)
2
Alzheimer Europe
40 associations in 35 countries
![Page 3: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/3.jpg)
European Dementia Monitor - Concept• Benchmarking of national dementia policies (comparison and
ranking)
• Possibility to repeat and show changes in rankings
• Lobbying tool for AE to present comparative data to European Parliament, European Commission and WHO/Europe (inequalities in access to care and treatment)
• Lobbying tool for national Alzheimer associations (compare national situation to other countries)
3
![Page 4: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/4.jpg)
European Dementia Monitor - Priority areas
• Availability of care services
• Affordability of care services (financing)
• Treatment-reimbursement of AD medicines
• Access to clinical trials
• Involvement of country in EU dementia research
• Recognition of dementia as a priority
• Dementia friendly Communities/Inclusiveness
• Recognition of legal rights
• Recognition of human rights
• Employment carer/employment support
4
![Page 5: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/5.jpg)
5
![Page 6: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/6.jpg)
Recognition of dementia as a priority• Is dementia recognised as a research priority?
• Is a national strategy in place or in development?
• Does the strategy have specific allocated funding?
• Is there a Government appointed person in charge of the coordination of dementia policies?
• Does the national Alzheimer’s association receive funding from Government for its core activities or central office?
• Does the national Alzheimer’s association receive funding from government programmes for projects or specific services?
6
![Page 7: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/7.jpg)
7
![Page 8: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/8.jpg)
Clinical Trials• Phase III
• Available in at least two European countries
• 9 clinical trials investigating different compounds (Aducanumab, Bexipiprazole, CAD106, Crenezumab, Idalopirdine, JNJ-54861911, LY3314814, RVT-101 and Varubecestat)
8
![Page 9: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/9.jpg)
9
![Page 10: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/10.jpg)
Dementia friendliness• Working group of people with dementia
• Dementia friends programme
• Dementia-friendly communities
– Developed concept
– In development
10
![Page 11: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/11.jpg)
11
![Page 12: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/12.jpg)
Overall ranking• Each section contributes 10% to the overall score
12
![Page 13: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/13.jpg)
13
![Page 14: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw](https://reader034.vdocuments.net/reader034/viewer/2022042402/5f13017a8ba46178a61425e1/html5/thumbnails/14.jpg)
Concluding remarks• Growing recognition of dementia as a European priority
– Need for increased funding and improved coordination at European and global level
– Need for benchmarking and comparison tools such as WHO Global Dementia Observatory
• Inequalities across European countries
– Need for dementia strategies and increased dementia awareness in all European countries
14